0
Catégories
Documents disponibles dans cette catégorie (256)
Ajouter le résultat dans votre panier Affiner la recherche
Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking / David Moore (2009)
Titre : Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking : systematic review and meta-analysis Type de document : texte imprimé Auteurs : David Moore, Auteur ; Paul Aveyard, Auteur ; Martin Connock, Auteur Année de publication : 2009 Importance : 9 p. Note générale : BMJ 2009338:b1024 - doi:10.1136/bmj.b1024 Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:substitution nicotiniqueIndex. décimale : TA 6.2.3.1 Substitution nicotinique Résumé : L'objectif de cette étude est de déterminer l'efficacité et la sécurité de la méthode de substitution nicotinique en thérapie assistée dans le but d'arrêter de fumer. disponible uniquement dans la bibliothèque virtuelle Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=3075 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 002460 TA 6.2.3.1 MOO E Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Effectiveness of motivational interviewing in influencing smoking cessation in pregnant and postpartum disadvantaged women / Catherine, B. Hayes (2011)
Titre : Effectiveness of motivational interviewing in influencing smoking cessation in pregnant and postpartum disadvantaged women Type de document : document électronique Auteurs : Catherine, B. Hayes, Auteur ; Claire Collins, Auteur ; Helen O'Carroll, Auteur Editeur : Oxford University Press Année de publication : 2011 Collection : Nicotine and Tobacco Research num. 15 Importance : p. 969-977 Langues : Anglais (eng) Catégories : [DIVERS] personne:par sexe:femme:femme enceinte
[TABAC] étude
[TABAC] sevrage tabagique
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche psychologique:entretien motivationnel
[TABAC] tabagisme:risque:facteur associé:grossesse
[TABAC] tabagisme:risque:facteur associé:précaritéIndex. décimale : TA 6.2.2 Approche psychologique (y compris entretien motivationnel) Résumé : Introduction:
Systematic assessments of Motivational Interviewing (MI) in smoking behavior have been rare to date. This study aimed to determine whether an integrated approach, involving staff training in MI techniques, was sufficient to affect change in smoking status or intensity in low-income pregnant and postpartum women.
Methods:
Overall, 500 consecutive smokers were recruited at first prenatal visit to public antenatal clinics. Following staff training,500 more were recruited (intervention group). Data were recorded at 28–32 weeks gestation, after birth, at 3–4 and 7–9 months postpartum.The primary outcome measure was self-reported continued abstinence from smoking verified by urinary cotinine analysis.
Changes in smoking intensity were also measured.
Results:
There was no significant difference in the proportion of smokers in the intervention and control groups who reported stopping smoking at 28–32 weeks gestation (8.2% vs. 8.8%; p = .73), 1 week after birth (8.6% vs. 11.4%; p = .14), 3–4 months after birth (5.8% vs. 4.8%; p = .48), or 7–9 months after birth (5.2% vs. 4.0%; p = .36). Although more cases were nonsmoking at the second visit, 14.8% [95% CI = 11.8–18.5] vs. 13.1% controls [95% CI = 10.3–16.6], this was not statistically significant.
Conclusions:
MI delivered at a number of time points during pregnancy and up to 9 months postpartum failed to affect quit rates. It may have had a small effect in preventing relapse among spontaneous quitters in late pregnancy though the validity of this remains uncertain.En ligne : https://doi.org/10.1093/ntr/nts225 Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=9693 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Effectiveness of smoking cessation therapies : a systematic review and meta-analysis Type de document : texte imprimé Auteurs : Ping Wu, Auteur ; Kumanan Wilson, Auteur ; Popey Dimoulas, Auteur Editeur : BioMed Central Année de publication : 2006 Collection : BMC Public Health num. Vol. 6 Importance : 16 p. Présentation : tab., ill. Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] étude:méta-analyse
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:bupropion
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:substitution nicotinique
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varéniclineIndex. décimale : TA 6.2.3 Approche pharmacologique Résumé : BACKGROUND:
Smoking remains the leading preventable cause of premature deaths. Several pharmacological interventions now exist to aid smokers in cessation. These include Nicotine Replacement Therapy [NRT], bupropion, and varenicline. We aimed to assess their relative efficacy in smoking cessation by conducting a systematic review and meta-analysis.
METHODS:
We searched 10 electronic medical databases (inception to Sept. 2006) and bibliographies of published reviews. We selected randomized controlled trials [RCTs] evaluating interventions for smoking cessation at 1 year, through chemical confirmation. Our primary endpoint was smoking cessation at 1 year. Secondary endpoints included short-term smoking cessation (approximately 3 months) and adverse events. We conducted random-effects meta-analysis and meta-regression. We compared treatment effects across interventions using head-to-head trials and when these did not exist, we calculated indirect comparisons.
RESULTS:
We identified 70 trials of NRT versus control at 1 year, Odds Ratio [OR] 1.71, 95% Confidence Interval [CI], 1.55-1.88, P =< 0.0001). This was consistent when examining all placebo-controlled trials (49 RCTs, OR 1.78, 95% CI, 1.60-1.99), NRT gum (OR 1.60, 95% CI, 1.37-1.86) or patch (OR 1.63, 95% CI, 1.41-1.89). NRT also reduced smoking at 3 months (OR 1.98, 95% CI, 1.77-2.21). Bupropion trials were superior to controls at 1 year (12 RCTs, OR1.56, 95% CI, 1.10-2.21, P = 0.01) and at 3 months (OR 2.13, 95% CI, 1.72-2.64). Two RCTs evaluated the superiority of bupropion versus NRT at 1 year (OR 1.14, 95% CI, 0.20-6.42). Varenicline was superior to placebo at 1 year (4 RCTs, OR 2.96, 95% CI, 2.12-4.12, P =< 0.0001) and also at approximately 3 months (OR 3.75, 95% CI, 2.65-5.30). Three RCTs evaluated the effectiveness of varenicline versus bupropion at 1 year (OR 1.58, 95% CI, 1.22-2.05) and at approximately 3 months (OR 1.61, 95% CI, 1.16-2.21). Using indirect comparisons, varenicline was superior to NRT when compared to placebo controls (OR 1.66, 95% CI 1.17-2.36, P = 0.004) or to all controls at 1 year (OR 1.73, 95% CI 1.22-2.45, P = 0.001). This was also the case for 3-month data. Adverse events were not systematically different across studies.
CONCLUSION:
NRT, bupropion and varenicline all provide therapeutic effects in assisting with smoking cessation. Direct and indirect comparisons identify a hierarchy of effectiveness.En ligne : https://bmcpublichealth.biomedcentral.com/articles/10.1186/1471-2458-6-300 Format de la ressource électronique : HTML Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7965 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Effectiveness of the electronic cigarette : an eight-week Flemish study with six-month follow-up on smoking reduction, craving and experienced benefits and complaints Type de document : texte imprimé Auteurs : Karolien Adriaens, Auteur ; Dinska Van Gucht, Auteur ; Paul Declerck, Auteur Editeur : Bâle [Suisse] : MDPI AG (Molecular Diversity Preservation International) Année de publication : novembre 2014 Collection : International Journal of Environmental Research and Public Health, ISSN 1660-4601 num. 11:11 Importance : p.11220-11248 Langues : Anglais (eng) Catégories : [DIVERS] géographie:Europe:Europe occidentale:Belgique
[TABAC] chimie du tabac:tabac fumé:cigarette:cigarette électronique
[TABAC] étude
[TABAC] sevrage tabagique
[TABAC] tabagisme:aspect psychologique:comportement:addictionIndex. décimale : TA 1.1.1 Cigarettes (« normales », électroniques, aromatisées,…) Résumé : Les cigarettes électroniques offrent aux fumeurs un moyen réaliste d’abandonner leur dépendance au tabac. Dans une nouvelle étude publiée dans la Revue internationale de la recherche environnementale et de la santé publique , des scientifiques de la KU Leuven ont déclaré que les cigarettes électroniques réduisaient avec succès l'envie de fumer des cigarettes de tabac, avec seulement des effets secondaires minimes. En ligne : https://doi.org/10.3390/ijerph111111220 Format de la ressource électronique : PDF, HTML Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8946 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 006972 TA 6.2.3.2 ECI Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Effectiveness of varenicline as an aid to smoking cessation / Hedwig Boudrez (2010)
Titre : Effectiveness of varenicline as an aid to smoking cessation : results of an inter-european observational study Type de document : texte imprimé Auteurs : Hedwig Boudrez, Auteur ; Christina Gratziou, Auteur ; Michael Messig, Auteur Année de publication : 2010 Importance : 1 p. Présentation : tab., graph. Langues : Anglais (eng) Catégories : [DIVERS] géographie:Europe
[TABAC] étude
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varéniclineIndex. décimale : TA 6.2.3.2 Autres produits Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8439 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 005036 TA 6.2.3.2 BOU E Affiche Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Effects of cannabis on lung function : a population-based cohort study Type de document : texte imprimé Auteurs : R.J. Hancox, Auteur Editeur : European Respiratory Society (ERS) Année de publication : 2010 Collection : European Respiratory Journal num. 35 (1) Importance : p. 42-47 Langues : Anglais (eng) Catégories : [DIVERS] anatomie:corps humain:appareil respiratoire
[TABAC] étude
[TABAC] tabagisme:risque:facteur associé:drogue:cannabis
[TABAC] tabagisme:tabagisme actifIndex. décimale : TA 1.1.5 Cannabis Résumé : The effects of cannabis on lung function remain unclear and may be different from those of tobacco. We compared the associations between use of these substances and lung function in a population-based cohort (n = 1,037). Cannabis and tobacco use were reported at ages 18, 21, 26 and 32 yrs. Spirometry, plethysmography and carbon monoxide transfer factor were measured at 32 yrs. Associations between lung function and exposure to each substance were adjusted for exposure to the other substance. Cumulative cannabis use was associated with higher forced vital capacity, total lung capacity, functional residual capacity and residual volume. Cannabis was also associated with higher airway resistance but not with forced expiratory volume in 1 s, forced expiratory ratio or transfer factor. These findings were similar among those who did not smoke tobacco. In contrast, tobacco use was associated with lower forced expiratory volume in 1 s, lower forced expiratory ratio, lower transfer factor and higher static lung volumes, but not with airway resistance. Cannabis appears to have different effects on lung function from those of tobacco. Cannabis use was associated with higher lung volumes, suggesting hyperinflation and increased large-airways resistance, but there was little evidence for airflow obstruction or impairment of gas transfer. En ligne : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3805041/ Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=2706 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Effects of cigarette smoking cessation on breastfeeding duration Type de document : document électronique Auteurs : Tara, M. Higgins, Auteur ; Stephen, T. Higgins, Auteur ; Sarah, H. Heil, Auteur Editeur : Oxford University Press Année de publication : 2010 Collection : Nicotine and Tobacco Research num. 12:5 Importance : p. 483–488 Langues : Anglais (eng) Catégories : [DIVERS] personne:par sexe:femme:femme enceinte
[TABAC] étude
[TABAC] prévention:santé:promotion de la santé:alimentation:allaitement
[TABAC] sevrage tabagiqueIndex. décimale : TA 3.2.2.7 Grossesse et fœtus Résumé : Introduction:
The purpose of this study was to use data from controlled trials to examine whether smoking cessation increases breastfeeding duration. Correlational studies have confirmedassociations between smoking status and breastfeeding duration, but whether smoking cessation increases breastfeeding duration has not been established.
Methods:
Participants ( N = 158) were smokers at the start of prenatal care who participated in controlled trials on smoking cessation. Women were assigned to either an incentive-based intervention wherein they earned vouchers exchangeable for retail items by abstaining from smoking or a control condition where they received comparable vouchers independent of smoking status. Treatments were provided antepartum through 12-week postpartum. Maternal reports of breastfeeding collected at 2-,
4-, 8-, 12-, and 24-week postpartum were compared between treatment conditions. Whether women were exclusively breastfeeding was not investigated.
Results:
The incentive-based treatment signifi cantly increased breastfeeding duration compared with rates observed among women receiving the control treatment, with signifi cant differences between treatment conditions observed at 8-week (41% vs. 26%; odds ratio [ OR ] = 2.7, 95% CI = 1.3– 5.6, p = .01) and 12-week
(35% vs. 17%; OR = 3.4, 95% CI = 1.5– 7.6, p = .002) postpartum. No significant treatment effects on breastfeeding were observed at other assessments. Changes in smoking status mediated the effects of treatment condition on breastfeeding duration.
Conclusions:
These results provide evidence from controlled studies that smoking cessation increases breastfeeding duration, which, to our knowledge, has not been previously reportedEn ligne : https://doi.org/10.1093%2Fntr%2Fntq031 Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=9576 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Effects of a generalised ban on smoking in bars and restaurants, Italy / N. Binkin (2007)
Titre : Effects of a generalised ban on smoking in bars and restaurants, Italy Type de document : texte imprimé Auteurs : N. Binkin, Auteur Editeur : International Union Against Tuberculosis and Lung Disease (IUATLD) Année de publication : 2007 Collection : International Journal of Tuberculosis and Lung Disease num. 11 (5) Importance : p. 522-257 Langues : Anglais (eng) Catégories : [DIVERS] géographie:Europe:Europe méridionale:Italie
[TABAC] étude
[TABAC] législation
[TABAC] législation:législation antitabac:interdiction de fumer
[TABAC] législation:milieu réglementé:horeca
[TABAC] tabagisme:tabagisme passifIndex. décimale : TA 9.2 Législation d’autres pays Résumé : En janvier 2005, l'Italie a mis en oeuvre une loi interdisant de fumer dans tous les lieux publics fermés. L'objectif de cette étude est de documenter les obstacles perçus ainsi que les effets de la loi et observer les comportements tabagiques des clients dans les bars et les restaurants. Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=2739 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 001485 TA 9.2 BIN E Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Effects of varenicline on smoking cessation in adults with stably treated current or past major depression / Robert M. Anthenelli (2013)
Titre : Effects of varenicline on smoking cessation in adults with stably treated current or past major depression : a randomized trial Type de document : texte imprimé Auteurs : Robert M. Anthenelli, Auteur ; Chad Morris, Auteur ; Tanya S. Ramey, Auteur Editeur : American College of Physicians Année de publication : 2013 Collection : Annals of internal medicine, ISSN 0003-4819 num. vol 159, n.6 Importance : p. 390-400 Présentation : ill., tab. Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varénicline
[TABAC] tabagisme:effet du tabac:effet psychiatrique:dépressionIndex. décimale : TA 6.2.3.1.4 Autres substituts nicotiniques Résumé : Background: Depression is overrepresented in smokers.
Objective: To evaluate smoking abstinence and changes in mood and anxiety levels in smokers with depression treated with varenicline versus placebo.
Design: Phase 4, multicenter, parallel, 1:1 allocation, double-blind, randomization trial. Randomization, stratified by antidepressant use and depression score at baseline, was blocked in sizes of 4. (ClinicalTrials.gov: NCT01078298)
Setting: 38 centers in 8 countries.
Participants: 525 adult smokers with stably treated current or past major depression and no recent cardiovascular events.
Intervention: Varenicline, 1 mg twice daily, or placebo for 12 weeks, with 40-week nontreatment follow-up.
Measurements: Primary outcome was carbon monoxide–confirmed continuous abstinence rate (CAR) for weeks 9 to 12. Other outcomes included CARs assessed during nontreatment follow-up and ratings of mood, anxiety, and suicidal ideation or behavior.
Results: 68.4% versus 66.5% of the varenicline and placebo groups, respectively, completed the study. Varenicline-treated participants had higher CARs versus placebo at weeks 9 to 12 (35.9% vs. 15.6%; odds ratio [OR], 3.35 [95% CI, 2.16 to 5.21]; P < 0.001), 9 to 24 (25.0% vs. 12.3%; OR, 2.53 [CI, 1.56 to 4.10]; P < 0.001), and 9 to 52 (20.3% vs. 10.4%; OR, 2.36 [CI, 1.40 to 3.98]; P = 0.001). There were no clinically relevant differences between groups in suicidal ideation or behavior and no overall worsening of depression or anxiety in either group. The most frequent adverse event was nausea (varenicline, 27.0%; placebo, 10.4%). Two varenicline-group participants died during the nontreatment phase.
Limitations: Some data were missing, and power to detect differences between groups was low in rare events. Smokers with untreated depression, with co-occurring psychiatric conditions, or receiving mood stabilizers and antipsychotics were not included.
Conclusion: Varenicline increased smoking cessation in smokers with stably treated current or past depression without exacerbating depression or anxiety.En ligne : https://annals.org/aim/fullarticle/1738494/effects-varenicline-smoking-cessation [...] Format de la ressource électronique : HTML Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7935 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Effects of varenicline on smoking cessation in mild-to moderate COPD / D.P. Tashkin (2010)
Titre : Effects of varenicline on smoking cessation in mild-to moderate COPD : a randomized controlled trial Type de document : texte imprimé Auteurs : D.P. Tashkin, Auteur ; Stephen I Rennard, Auteur ; J. Taylor Hays, Auteur Editeur : American College of Chest Physicians Année de publication : 2010 Collection : Chest, ISSN 0012-3692 Importance : 30 p. Présentation : tab. Langues : Français (fre) Catégories : [TABAC] étude
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varéniclineIndex. décimale : TA 6.2.3.1.4 Autres substituts nicotiniques Résumé : BACKGROUND:
Smoking is the most important risk factor for COPD and accelerates its progression. Despite the health implications, a large proportion of patients with COPD continue to smoke, so finding effective smoking cessation interventions for this population is paramount. To our knowledge, this is the first randomized clinical trial to compare the efficacy and safety of varenicline tartrate vs placebo in smokers with mild to moderate COPD.
METHODS:
In a 27-center, double-blind, multinational study, 504 patients with mild to moderate COPD (postbronchodilator FEV1/FVC, <70%; FEV1 percent predicted normal value, ≥50%) and without known psychiatric disturbances were randomized to receive varenicline (n=250) or placebo (n=254) for 12 weeks, with a 40-week nontreatment follow-up. The primary end point was carbon monoxide-confirmed continuous abstinence rate (CAR) for weeks 9 to 12. A secondary end point was CAR for weeks 9 to 52.
RESULTS:
CAR for weeks 9 to 12 was significantly higher for patients in the varenicline group (42.3%) than for those in the placebo group (8.8%) (OR, 8.40; 95% CI, 4.99-14.14; P<.0001). CAR in the patients treated with varenicline remained significantly higher than in those treated with placebo through weeks 9 to 52 (18.6% vs 5.6%) (OR, 4.04; 95% CI, 2.13-7.67; P<.0001). Nausea, abnormal dreams, upper-respiratory tract infection, and insomnia were the most commonly reported adverse events (AEs) for patients in the varenicline group. Serious AEs were infrequent in both treatment groups. Two patients in the varenicline group and one patient in the placebo group died during the study. Reports of psychiatric AEs were similar for both treatment groups.
CONCLUSIONS:
Varenicline was more efficacious than placebo for smoking cessation in patients with mild to moderate COPD and demonstrated a safety profile consistent with that observed in previous trials.Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7933 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 005474 TA 6.2.3.1.4 TAS E Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Effets sur la santé de la consommation quotidienne ou quasi quotidienne à long terme de cannabis / Axelle Marchand (2022-02)
Titre : Effets sur la santé de la consommation quotidienne ou quasi quotidienne à long terme de cannabis : Synthèse des connaissances Type de document : document électronique Auteurs : Axelle Marchand, Auteur ; Marie-Eve Levasseur, Auteur Editeur : Institut National de Santé Publique du Québec (INSPQ) Année de publication : 2022-02 Importance : 76 p. Présentation : ill., tab., graph. Langues : Français (fre) Catégories : [DIVERS] anatomie
[DIVERS] géographie:Amérique:Amérique du Nord:Canada:Québec
[TABAC] chimie du tabac
[TABAC] étude
[TABAC] prévention:santé:santé mentale
[TABAC] sevrage tabagique
[TABAC] tabagisme:effet du tabac
[TABAC] tabagisme:risque:facteur associé:alcool
[TABAC] tabagisme:risque:facteur associé:consommation
[TABAC] tabagisme:risque:facteur associé:drogue:cannabis
[TABAC] tabagisme:risque:facteur associé:génétiqueIndex. décimale : TA 0.7 Autres drogues Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=9853 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Les effets du tabac sur l'aptitude physique / D. Barrault (1986)
Titre : Les effets du tabac sur l'aptitude physique Type de document : texte imprimé Auteurs : D. Barrault, Auteur Editeur : Symbioses Année de publication : 1986 Collection : Symbioses num. 18 (3) Importance : p.211-215 Langues : Français (fre) Catégories : [TABAC] étude
[TABAC] tabagisme:effet du tabac
[TABAC] tabagisme:risque:facteur associé:sportIndex. décimale : TA 4.1.2 Influence sur le mode de vie Résumé : La nocivité du tabac est manifeste à la lecture de multiples travaux qui ont essentiellement porté sur les produits fumés, notamment les cigarettes. Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=2997 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 002138 TA 4.1.2 BAR E Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation / Cheryl Oncken (2006)
Titre : Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation Type de document : texte imprimé Auteurs : Cheryl Oncken, Auteur ; David H. Gonzales, Auteur ; Mitchell Nides, Auteur Editeur : American Medical Association (AMA) Année de publication : 2006 Collection : Archives of internal medicine, ISSN 0003-9926 num. Vol. 166 Importance : p. 1571-1577 Présentation : tab., graph. Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varéniclineIndex. décimale : TA 6.2.3.1.4 Autres substituts nicotiniques Résumé : Abstract
BACKGROUND:
The selective nicotinic acetylcholine receptor partial agonist, varenicline tartrate, represents a novel type of therapy for smoking cessation. This study evaluated the efficacy, safety, and tolerability of 4 varenicline dose regimens, 2 with progressive dosing over the first week (eg, titrated) and 2 with a fixed dosing schedule (eg, non-titrated), for promoting smoking cessation.
METHODS:
This multicenter, double-blind, placebo-controlled study randomized healthy smokers (aged 18-65 years) to varenicline tartrate, 0.5 mg twice daily nontitrated (n = 129), 0.5 mg twice daily titrated (n = 130), 1.0 mg twice daily nontitrated (n = 129), 1.0 mg twice daily titrated (n = 130), or placebo (n = 129) for 12 weeks to aid in smoking cessation. A 40-week follow-up period assessed long-term efficacy. The primary efficacy measures were the carbon monoxide-confirmed 4-week continuous quit rates by pooled dosage group for weeks 4 through 7 and 9 through 12 and the continuous abstinence rates for weeks 9 through 52.
RESULTS:
Weeks 9 through 12 continuous quit rates were greater in the 1.0-mg group (49.4%) and the 0.5-mg group (44.0%) vs placebo (11.6%; P<.001 vs both doses). Weeks 9 through 52 abstinence rates were greater in the 1.0-mg group (22.4%; P<.001) and the 0.5-mg group (18.5%; P<.001) vs placebo (3.9%). Varenicline was generally well tolerated, with nausea occurring in 16% to 42% of varenicline-treated subjects. Reports of nausea were lower for the titrated vs nontitrated dosing and infrequently led to medication discontinuation.En ligne : https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/410803 Format de la ressource électronique : HTML Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7951 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Efficacy of varenicline, an alpha-4-beta-2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation / Douglas E. Jorenby (01/06/2006)
Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 001432 TA 6.2.3.1.4 JOR E Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Electronic cigarette marketing and smoking behaviour in adolescence : a cross-sectional study Type de document : texte imprimé Auteurs : Julia Hansen, Auteur ; Reiner Hanewinkel, Auteur ; Matthis Morgenstern, Auteur Editeur : European Respiratory Society (ERS) Année de publication : 2018-09-08 Collection : Breathe, ISSN 1810-6838 Importance : 10 p. Langues : Anglais (eng) Catégories : [DIVERS] géographie:Europe:Europe occidentale:Allemagne
[DIVERS] personne:famille:adolescent
[TABAC] économie du tabac:marketing:publicité
[TABAC] étudeIndex. décimale : TA 1.1.1 Cigarettes (« normales », électroniques, aromatisées,…) En ligne : https://openres.ersjournals.com/content/4/4/00155-2018 Format de la ressource électronique : HTML, PDF Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8974 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 006881 TA 1.1.1 HAN E Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !